|
1) De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010; 19: 409-14
|
|
|
|
2) Agudo S, Perez-Perez G, Alarcon T, et al. Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. Rev Esp Quimioter. 2011; 24: 32-6
|
|
|
|
|
|
3) Cerqueira L, Fernandes RM, Ferreira RM, et al. PNA-FISH as a new diagnostic method for the determination of clarithromycin resistance of Helicobacter pylori. BMC Microbiol. 2011; 11: 101
|
|
|
|
|
|
4) Qureshi NN, Morikis D, Schiller NL. Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates. Antimicrob Agents Chemother. 2011; 55: 101-9
|
|
|
|
|
5) Nishizawa T, Suzuki H, Tsugawa H, et al. Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication. Antimicrob Agents Chemother. 2011; 55: 3012-4
|
|
|
|
|
|
6) Raymond J, Lamarque D, Kalach N, et al. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter. 2010; 15: 21-7
|
|
|
|
|
|
7) Kaakoush NO, Asencio C, Megraud F, et al. A redox basis for metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2009; 53: 1884-91
|
|
|
|
|
|
8) Tsugawa H, Suzuki H, Satoh K, et al. Two amino acids mutation of ferric uptake regulator determines Helicobacter pylori resistance to metronidazole. Antioxid Redox Signal. 2011; 14: 15-23
|
|
|
|
|
|
9) Choi SS, Chivers PT, Berg DE. Point mutations in Helicobacter pylori's fur regulatory gene that alter resistance to metronidazole, a prodrug activated by chemical reduction. PLoS One. 2011; 6: e18236
|
|
|
|
|
|
10) Matsuzaki J, Suzuki H, Tsugawa H, et al. Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy. J Gastroenterol Hepatol. 2010; 25 Suppl 1: S7-10
|
|
|
|
|
|
11) Nishizawa T, Suzuki H, Umezawa A, et al. Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J Clin Microbiol. 2007; 45: 303-5
|
|
|
|
|
|
12) Nishizawa T, Suzuki H, Kurabayashi K, et al. Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother. 2006; 50: 1538-40
|
|
|
|
|
|
13) Yamade M, Sugimoto M, Uotani T, et al. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol. 2011; Epub ahead of print
|
|
|
|
|
|
14) Suzuki H, Nishizawa T, Muraoka H, et al. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother. 2009; 53: 1720-1
|
|
|
|
|
|
15) Murakami K, Okimoto T, Kodama M, et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother. 2009; 53: 3097-9
|
|
|
|
|
|
16) Hirata K, Suzuki H, Nishizawa T, et al. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol. 2010; 25 Suppl 1: S75-9
|
|
|
|
|
|
17) Mehrabadi JF, Sirous M, Daryani NE, et al. Assessing the role of the RND efflux pump in metronidazole resistance of Helicobacter pylori by RT-PCR assay. J Infect Dev Ctries. 2011; 5: 88-93
|
|
|
|
|
|
18) Tsugawa H, Suzuki H, Muraoka H, et al. Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori. Biochem Biophys Res Commun. 2011; 404: 656-60
|
|
|
|
|
|
19) Zhang Z, Liu ZQ, Zheng PY, et al. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol. 2010; 16: 1279-84
|
|
|
|
|
|
20) Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011; 377: 905-13
|
|
|
|
|